SOUTH SAN FRANCISCO, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the year ending December 31, 2010. The Company also provided an update on recent clinical and corporate progress and outlook for 2011.
